Langer Seppo W
Copenhagen University Hospital, Rigshospitalet, Department of Oncology, Section 5073, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Expert Rev Anticancer Ther. 2007 Aug;7(8):1081-8. doi: 10.1586/14737140.7.8.1081.
Accidental extravasation of anthracycline-containing anticancer chemotherapy is a feared complication that may lead to progressive tissue damage. The condition may require extensive surgical intervention and often has severe long-term effects. Until a short while ago, there has been no effective treatment against the devastating effect of extravasated anthracycline. However, dexrazoxane has proven highly effective in preventing necrosis in both preclinical and clinical studies and is now approved in Europe (Savene), and has orphan drug status in the USA (Totect) for this indication. Hence, it is the first and only proven effective antidote against anthracycline extravasation injuries.
含蒽环类药物的抗癌化疗药物意外外渗是一种可怕的并发症，可能导致进行性组织损伤。这种情况可能需要广泛的手术干预，并且常常具有严重的长期影响。直到不久前，还没有针对外渗蒽环类药物的破坏性影响的有效治疗方法。然而，在临床前和临床研究中，右丙亚胺已被证明在预防坏死方面非常有效，目前在欧洲已获批准（商品名Savene），在美国针对该适应症具有孤儿药地位（商品名Totect）。因此，它是首个也是唯一经证实有效的抗蒽环类药物外渗损伤的解毒剂。
